Evaluation of N-Hydroxy-, N-Metoxy-, and N-Acetoxybenzoyl-Substituted Derivatives of Thymine and Uracil as New Substances for Prevention and Treatment of Long-Term Complications of Diabetes Mellitus


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

New uracil and thymine derivatives, N1-,N3- and N1,N3-(RO-benzoyl)-(1H,3H)-pyrimidine- 2,4-diones, were synthesized (RO- is hydroxy, acetoxy- or methoxy-group). The compounds were studied in a complex of in vitro tests for the ability to inhibit the development of long-term complications of diabetes. Their ability to cleave cross-links of proteins has been evaluated. The most significant ways of pharmacological correction of thrombosis, angio-, nephro-, encephalo-, and cardiopathy, antiglycation, chelating, and antiplatelet activities, have been established. The most active compound in terms of antiplatelet action, N1- hydroxybenzoyluracil, exceeded acetylsalicylic acid by ~44%. In terms of their ability to chelate copper (II) cations, all compounds (with the exception of 1,3-bis(3-hydroxybenzoyl)-(1H,3H)-pyrimidine-2,4-dione that was not not studied in this test) showed the activity, whose IC50 fell in the range between that for pioglitazone (44.1 μM) and pyridoxamine (136.7 μM) comparison drugs. The best antiglycation effect at the 1 mM concentration was observed for N1,N3-bismethoxy- and N1,N3-bisacetoxybenzoyl derivatives of thymine. The maximum activity to cleave cross-links of proteins (C = 1 mM), comparable to that of alagebrium, was established for 1,3-bis(4-methoxybenzoyl)uracil, for which also high rates of other estimated activities were noted. Thus, the N1-,N3- and N1,N3-(RO-benzoyl) derivatives of uracil and thymine are promising basiсs for creating drugs that suppress the development of long-term complications of diabetes.

作者简介

A. Spasov

Volgograd State Medical University; Volgograd Medical Scientific Center; Scientific Institute of Pharmacology of VSMU

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131; Volgograd, 400081; Volgograd, 400001

A. Brel

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

R. Litvinov

Volgograd State Medical University; Scientific Institute of Pharmacology of VSMU

编辑信件的主要联系方式.
Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131; Volgograd, 400001

S. Lisina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

A. Kucheryavenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

Yu. Budaeva

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

O. Salaznikova

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

A. Rashchenko

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

D. Shamshina

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

V. Batrakov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

A. Ivanov

Volgograd State Medical University

Email: litvinov.volggmu@mail.ru
俄罗斯联邦, Volgograd, 400131

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Ltd., 2018